Filtered By:
Specialty: Cardiology
Condition: Thrombosis
Drug: Coumadin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 325 results found since Jan 2013.
French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children
Rev Med Interne. 2023 Sep 19:S0248-8663(23)00711-7. doi: 10.1016/j.revmed.2023.08.004. Online ahead of print.ABSTRACTAntiphospholipid syndrome (APS) is a chronic autoimmune disease involving vascular thrombosis and/or obstetric morbidity and persistent antibodies to phospholipids or certain phospholipid-associated proteins. It is a rare condition in adults and even rarer in children. The diagnosis of APS can be facilitated by the use of classification criteria based on a combination of clinical and biological features. APS may be rapidly progressive with multiple, often synchronous thromboses, resulting in life-threatening...
Source: Atherosclerosis - September 21, 2023 Category: Cardiology Authors: Z Amoura B Bader-Meunier C Bal Dit Sollier A Belot Y Benhamou H Bezanahary F Cohen N Costedoat-Chalumeau L Darnige L Drouet E Elefant A Harroche M Lambert T Martin I Martin-Toutain A Mathian A Mekinian M Pineton De Chambrun L de Pontual D Wahl C Yelnik S Source Type: research
Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
CONCLUSIONS: Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03178864.PMID:37675613 | DOI:10.1161/STROKEAHA.123.044113
Source: Atherosclerosis - September 7, 2023 Category: Cardiology Authors: Thalia S Field Vanessa Dizonno Mohammed A Almekhlafi Fouzi Bala Ibrahim Alhabli Hubert Wong Monica Norena Maria Karina Villaluna Princess King-Azote Namali Ratnaweera Steven Mancini Stephen C Van Gaal Laura K Wilson Brett R Graham Luciano A Sposato Dylan Source Type: research
Quest for the Perfect Anticoagulant
The current referenced meta-analysis study by Selvaraj et al1 examines the relative merits of anticoagulation with a direct oral anticoagulant (DOAC) versus vitamin K antagonist (VKA) after transcatheter aortic valve implantation (TAVI) in patients meeting the indications for anticoagulation because of atrial fibrillation (AF). Although guidelines vary, the general consensus appears to indicate noninferiority to superiority of DOACs in the treatment of nonvalvular AF. In the landmark Apixiban for Reduction In Stroke and Other Thromboemoblic Events in Atrial Fibrillation trial comparing apixaban to warfarin in patients with...
Source: The American Journal of Cardiology - July 27, 2023 Category: Cardiology Authors: Bryant Fisher, Danny Chu Source Type: research
Risk Of Pump Thrombosis With Once Daily Enoxaparin For Anticoagulation Bridging In Patients With Heartmate III
Most centers bridge patients with Left Ventricular Assist Device (LVAD) with heparin drip to avoid thromboembolic complications including stroke and pump thrombosis based on data from HeartMate II. Because of improved hemocompatibility of third generation HeartMateIII (HM3), particularly the decreased risk of in-pump thrombosis, outpatient treatment dose of low molecule weight heparin (LWMH) like Enoxaparin has been used to bridge to warfarin when the INR is subtherapeutic. Once daily dosing has been used in select patients with higher bleeding risk.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Modar Alom, Gurjaspreet Bhattal, Nitin Kabra, David Rawitscher, Amit Alam, Cesar Guerrero-Miranda, Sandra Carey, Timothy George, Aasim Afzal Tags: 180 Source Type: research
Can Warfarin be replaced by non-vitamin K anticoagulants in prosthetic valves?
In this report, the authors discussed the published data related to NOACs use in prosthetic valves highlighting the proposed mechanisms of NOACs failure and other controversial data regarding their efficacy and safety in prosthetic valves.EXPERT OPINION: Although NOACs have proven to be even safer and more effective alternatives to vitamin K antagonists (VKAs) in several indications for anticoagulation, the data regarding their safety and efficacy in prosthetic heart valves is still debatable. The controversial data regarding NOACs use in prosthetic valves renders it difficult to define specific guideline-recommendation fo...
Source: Expert Review of Cardiovascular Therapy - November 24, 2022 Category: Cardiology Authors: Mahmoud Abdelnabi Juthipong Benjanuwattra Ashraf Ahmed Abdallah Almaghraby Source Type: research
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
